Myconostica Ltd, the medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the immediate appointment of Mr David Evans as independent Non-Executive Director.
Myconostica, which is based in the UK but has an international network of distributors, has a number of molecular diagnostic products already on the market, and is developing a portfolio of additional tests with the aim of providing healthcare professionals with a complete diagnostic toolkit for life-threatening fungal infections.
As the former CFO of Shield Diagnostics Ltd, David guided the business through its IPO and then, as its CEO, through its merger with Axis Biochemical ASA to form Axis-Shield plc, a fully listed diagnostics company. He is currently Chairman or Non-Executive Director of a number of companies within the diagnostic and life science space including Epistem Holdings plc, Immunodiagnostic Systems Holdings plc and Omega Diagnostics Group plc, all AIM listed diagnostic companies. David was Chairman of Manchester-based personalised medicine/ companion diagnostic business DxS Ltd for three years until June 2009 and during this time he steered DxS’s transformation from a reference genetics laboratory to a thriving molecular diagnostics products company.
Myconostica Ltd
